The KRT5 Knockout 769-P Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human KRT5 gene in the immortalized renal epithelial cell line 769-P. This loss-of-function model contains a heterogeneous mixture of cells with diverse CRISPR/Cas9-mediated gene disruptions, preserving population-level diversity while avoiding clonal adaptation artifacts. Supplied as an early-passage frozen stock, the cells are designed for immediate culture and provide a robust experimental system for investigating keratin intermediate filament biology in a carcinoma context.
The 769-P host cell line was established from a primary human clear cell renal cell carcinoma, and it is widely used as a model for kidney cancer research. Exhibiting characteristic features such as aberrant VHL signaling and altered metabolic pathways, 769-P cells recapitulate key aspects of renal adenocarcinoma and serve as a versatile platform for studying oncogenic mechanisms, epithelial transformation, and therapeutic responses in kidney-derived malignancies.
KRT5 encodes keratin 5, a type II intermediate filament protein that partners with keratin 14 (KRT14) to form the cytoskeletal network providing mechanical integrity to basal epithelial cells. Transcription is activated by the p63 transcription factor (??Np63??) and EGFR ligands (EGF, TGF-??), with modulation by oncostatin M, IL-1??, and TGF-??1. At adhesive junctions, KRT5-KRT14 filaments connect to hemidesmosomes and desmosomes through plectin, BPAG1, and desmoplakin, linking to integrin ??4 (ITGB4) and plakoglobin. Intracellularly, KRT5 scaffolds 14-3-3?? (SFN) and filamin A, influencing Akt and ERK phosphorylation. Therefore, KRT5 loss disrupts mechanical stability, adhesive structures, and survival signaling, promoting sensitivity to anoikis and altered migration.
In the 769-P renal cell carcinoma background, KRT5 knockout provides a targeted model to dissect the roles of keratin filaments in malignant behavior. Although KRT5 is predominantly associated with stratified epithelia, its expression in certain urogenital carcinomas, including subsets of kidney and bladder cancers, has been linked to cellular differentiation status and metastatic capacity. Ablation of KRT5 in this context permits investigation of its potential tumor-suppressive or oncogenic functions and the interplay between p63-driven transcriptional programs and EGFR-mediated proliferation. This system also enables analysis of epithelial-mesenchymal transition dynamics and the contribution of intermediate filaments to drug resistance mechanisms in renal cancer.
The polyclonal knockout cells are suited for Western blotting and immunofluorescence to verify KRT5 ablation and keratin network disruption. Functional assays encompass Transwell migration/invasion, cell adhesion measurements, and apoptosis testing. Transcriptomic profiling via RNA-seq reveals KRT5-dependent expression changes, co-immunoprecipitation maps altered interactions, and phospho-signaling analysis monitors Akt/ERK status. Drug sensitivity studies assess the role of KRT5 in resistance to therapies. This flexible platform supports cancer cell biology, EMT studies, and pharmacological screening. For additional details, please contact Ascent Research.
